|
|
|
Stem Cell Related Patent Number US6048524
| Title: | In vivo production and delivery of erythropoietin for gene therapy | | Inventors: | Selden, Richard F; Wellesley, MA, USA
Treco, Douglas; Arlington, MA, USA
Heartlein, Michael W.; Boxborough, MA, USA | | Summary: | This invention describes transfected primary and secondary somatic cells of vertebrate origin, particularly mammalian origin, transfected with exogenous genetic material (DNA) which encodes erythropoietin or an insulinotropin [e.g., derivatives of glucagon-like peptide 1(GLP-1)]. Also disclosed are methods by which primary and secondary cells are transfected to include exogenous genetic material encoding erythropoietin or an insulinotropin, methods of producing clonal cell strains or heterogenous cell strains which express eruthropoietin or an insulinotropin, methods of gene therapy in which the transfected primary or secondary cells are used, and the methods of producing antibodies using the transfected primary or secondary cells. This represents a further expansion of previous applications filed by the same assignee and inventors. | | Abstract: | The present invention relates to transfected primary and secondary somatic cells of vertebrate origin, particularly mammalian origin, transfected with exogenous genetic material (DNA) which encodes erythropoietin or an insulinotropin [e.g., derivatives of glucagon-like peptide 1(GLP-1)], methods by which primary and secondary cells are transfected to include exogenous genetic material encoding erythropoietin or an insulinotropin, methods of producing clonal cell strains or heterogenous cell strains which express eruthropoietin or an insulinotropin, methods of gene therapy in which the transfected primary or secondary cells are used, the methods of producing antibodies using the transfected primary or secondary cells. | | US Patent Website: | Click Here for Full Text of Patent | | Title Number: | US6048524 | | Application Number: | US1995000446909 | | Date Filed: | 22/05/1995 | | Date Published: | 11/04/2000 | | Assignee: | Transkaryotic Therapies, Inc., Cambridge, MA, USA |
|
|
